advertisement

Topcon

Roberti G 11

Showing records 1 to 11 | Display all abstracts from Roberti G

74700 Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry
Roberti G
PLoS ONE 2017; 12: e0186793
74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Di Zazzo A
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677
74700 Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry
Manni G
PLoS ONE 2017; 12: e0186793
74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Roberti G
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677
74700 Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry
Riva I
PLoS ONE 2017; 12: e0186793
74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Mashaghi A; Abud TB
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677
74700 Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry
Holló G
PLoS ONE 2017; 12: e0186793
74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Pavese D
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677
74700 Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry
Quaranta L; Agnifili L
PLoS ONE 2017; 12: e0186793
74615 Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Bonini S
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 670-677
74700 Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry
Figus M; Giammaria S; Rastelli D; Oddone F
PLoS ONE 2017; 12: e0186793

Issue 19-1

Change Issue


advertisement

Oculus